دورية أكاديمية
أعرض في EDS

Multiepitope Subunit Peptide-Based Nanovaccine against Porcine Circovirus Type 2 (PCV2) Elicited High Antibody Titers in Vaccinated Mice.

التفاصيل البيبلوغرافية
العنوان: Multiepitope Subunit Peptide-Based Nanovaccine against Porcine Circovirus Type 2 (PCV2) Elicited High Antibody Titers in Vaccinated Mice.
المؤلفون: Duong VT; School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia., Koirala P; School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia., Chen SR; Australian Institute of Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD 4072, Australia., Monteiro MJ; Australian Institute of Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD 4072, Australia., Skwarczynski M; School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia., Toth I; School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia.; School of Pharmacy, The University of Queensland, Woolloongabba, QLD 4102, Australia.
المصدر: Molecules (Basel, Switzerland) [Molecules] 2023 Feb 28; Vol. 28 (5). Date of Electronic Publication: 2023 Feb 28.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049 (Electronic) Linking ISSN: 14203049 NLM ISO Abbreviation: Molecules Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, c1995-
مواضيع طبية MeSH: Circovirus* , Swine Diseases*/prevention & control , Viral Vaccines*, Swine ; Animals ; Mice ; Antibodies, Viral ; Peptides ; Epitopes ; Adjuvants, Immunologic
مستخلص: Porcine circovirus 2 (PCV2) infection is one of the most serious threats to the swine industry. While the disease can be prevented, to some extent, by commercial PCV2a vaccines, the evolving nature of PCV2 necessitates the development of a novel vaccine that can compete with the mutations of the virus. Thus, we have developed novel multiepitope vaccines based on the PCV2b variant. Three PCV2b capsid protein epitopes, together with a universal T helper epitope, were synthesized and formulated with five delivery systems/adjuvants: complete Freund's adjuvant, poly(methyl acrylate) (PMA), poly(hydrophobic amino acid), liposomes and rod-shaped polymeric nanoparticles built from polystyrene-poly( N -isopropylacrylamide)-poly( N -dimethylacrylamide). Mice were subcutaneously immunized with the vaccine candidates three times at three-week intervals. All vaccinated mice produced high antibody titters after three immunizations as analyzed by the enzyme-linked immunosorbent assay (ELISA), while mice vaccinated with PMA-adjuvanted vaccine elicited high antibody titers even after a single immunization. Thus, the multiepitope PCV2 vaccine candidates designed and examined here show strong potential for further development.
References: Int J Nanomedicine. 2022 Apr 05;17:1593-1608. (PMID: 35411142)
Vet Microbiol. 2012 May 25;157(1-2):13-22. (PMID: 22176764)
Vet Q. 2002 Sep;24(3):109-24. (PMID: 12400999)
Methods Mol Biol. 2022;2412:145-178. (PMID: 34918245)
Braz J Microbiol. 2018 Apr - Jun;49(2):351-357. (PMID: 29128395)
Crit Rev Clin Lab Sci. 1987;25(4):275-311. (PMID: 3322675)
Vet Microbiol. 2007 Dec 15;125(3-4):244-55. (PMID: 17611048)
Bioconjug Chem. 2021 Nov 17;32(11):2307-2317. (PMID: 34379392)
J Mater Chem B. 2016 Sep 7;4(33):5496-5509. (PMID: 30774955)
Annu Rev Chem Biomol Eng. 2010;1:149-73. (PMID: 22432577)
Carbohydr Polym. 2020 Feb 1;229:115423. (PMID: 31826462)
J Med Chem. 2021 Mar 11;64(5):2648-2658. (PMID: 33529034)
Pharm Res. 2009 Jan;26(1):244-9. (PMID: 18548338)
Vaccines (Basel). 2021 Sep 17;9(9):. (PMID: 34579271)
Comput Biol Med. 2021 Jun;133:104420. (PMID: 33930764)
Methods Mol Biol. 2022;2412:295-307. (PMID: 34918252)
Vaccines (Basel). 2019 Jul 01;7(3):. (PMID: 31266253)
J Allergy Clin Immunol. 2022 Jul;150(1):157-169.e10. (PMID: 35278494)
Chem Sci. 2016 Feb 1;7(2):842-854. (PMID: 28791117)
Vet Immunol Immunopathol. 2020 Feb;220:109995. (PMID: 31877484)
Angew Chem Int Ed Engl. 2010 Aug 2;49(33):5742-5. (PMID: 20818757)
Nanomedicine (Lond). 2021 Mar;16(6):497-516. (PMID: 33683164)
Vet Res. 2014 Mar 06;45:29. (PMID: 24602200)
Biomaterials. 2014 Jul;35(22):5862-74. (PMID: 24746228)
Nanomedicine (Lond). 2014 Jan;9(1):35-43. (PMID: 23611619)
Ther Deliv. 2016 Sep;7(9):601-9. (PMID: 27582233)
Sci Adv. 2020 Jan 29;6(5):eaax2285. (PMID: 32064333)
Acta Biomater. 2015 Mar;14:104-14. (PMID: 25484331)
PLoS One. 2018 Dec 6;13(12):e0208585. (PMID: 30521609)
Eur J Med Chem. 2019 Oct 1;179:100-108. (PMID: 31247372)
J Control Release. 2015 Dec 28;220(Pt A):141-148. (PMID: 26437263)
J Nanobiotechnology. 2017 Nov 17;15(1):83. (PMID: 29149896)
Vaccine. 2014 Sep 8;32(40):5221-7. (PMID: 25066738)
Tuberculosis (Edinb). 2023 Mar;139:102307. (PMID: 36706503)
Vaccines (Basel). 2022 Jul 29;10(8):. (PMID: 36016100)
Vaccine. 2003 Nov 7;21(31):4565-75. (PMID: 14575769)
Vet Res. 2022 Feb 18;53(1):12. (PMID: 35180885)
ACS Med Chem Lett. 2019 Jul 24;10(9):1253-1259. (PMID: 31531193)
Immunol Cell Biol. 2004 Oct;82(5):488-96. (PMID: 15479434)
Immunology. 1997 Oct;92(2):252-8. (PMID: 9415034)
Vaccine. 2017 Jun 8;35(26):3401-3408. (PMID: 28511853)
Immunity. 2010 Oct 29;33(4):492-503. (PMID: 21029960)
Nanoscale Res Lett. 2013 Feb 22;8(1):102. (PMID: 23432972)
Vet Immunol Immunopathol. 2020 May;223:110034. (PMID: 32278900)
J Gen Virol. 2012 Jul;93(Pt 7):1548-1555. (PMID: 22492916)
Clin Diagn Lab Immunol. 2002 Jan;9(1):33-40. (PMID: 11777826)
Vet Microbiol. 2013 Apr 12;163(1-2):177-83. (PMID: 23305615)
J Immunol. 2004 Sep 1;173(5):3148-54. (PMID: 15322175)
Biomacromolecules. 2019 Feb 11;20(2):625-634. (PMID: 30157649)
Nat Rev Immunol. 2010 Nov;10(11):787-96. (PMID: 20948547)
Nat Rev Drug Discov. 2007 May;6(5):404-14. (PMID: 17473845)
Int J Nanomedicine. 2019 Sep 16;14:7533-7548. (PMID: 31571862)
Viruses. 2017 May 06;9(5):. (PMID: 28481275)
Vaccine. 2016 Nov 4;34(46):5677-5688. (PMID: 27693020)
Hum Vaccin Immunother. 2014;10(3):778-96. (PMID: 24300669)
Expert Rev Vaccines. 2015 Mar;14(3):447-59. (PMID: 25308798)
J Control Release. 2021 Mar 10;331:296-308. (PMID: 33450322)
J Virol. 2003 Aug;77(16):8801-11. (PMID: 12885899)
Vaccine. 2005 Aug 31;23(37):4589-97. (PMID: 15927323)
Int J Nanomedicine. 2015 Feb 02;10:975-99. (PMID: 25678787)
معلومات مُعتمدة: APP1132975 National Health and Medical Research Council; DP210101280 Australian Research Council
فهرسة مساهمة: Keywords: adjuvant; block copolymers; liposome; nanoparticles; peptide-based vaccine; poly(methyl acrylate); polyleucine; porcine circovirus; rods
المشرفين على المادة: 0 (Antibodies, Viral)
0 (Viral Vaccines)
0 (Peptides)
0 (Epitopes)
0 (Adjuvants, Immunologic)
تواريخ الأحداث: Date Created: 20230311 Date Completed: 20230314 Latest Revision: 20230314
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10005372
DOI: 10.3390/molecules28052248
PMID: 36903494
قاعدة البيانات: MEDLINE
الوصف
تدمد:1420-3049
DOI:10.3390/molecules28052248